RecruitingNot ApplicableNCT06989177

Probiotic Intervention on Body Weight

An Interventional Study Investigating the Effects of Probiotics on Body Weight and Metabolic Homeostasis


Sponsor

Chinese Academy of Sciences

Enrollment

140 participants

Start Date

Jun 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a randomized controlled trial with 120 overweight or obese (body-mass index, BMI, ≥ 24 kg/m²) participants and 20 normal-weight participants. Twelve weeks of energy-restricted nutritional and lifestyle intervention with placebo, Lactobacillus paracasei LC-19 (LC-19), or semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1RA) will be randomly conducted in the overweight or obese participants. The primary goal is to clarify the roles of LC-19 and semaglutide in weight reduction and in improving energy, glucose, and lipid metabolism, while also comparing side effects, adverse events, and long-term outcomes such as weight regain between these two interventions. In addition, the study will explore key factors affecting intervention response to provide evidence for optimizing individualized intervention strategies.


Eligibility

Min Age: 20 YearsMax Age: 50 Years

Inclusion Criteria5

  • Aged 20 to 50 years.
  • Normal-weight participants: 18.5 kg/m² ≤ Body Mass Index (BMI) \< 24 kg/m².
  • Overweight or obese participants:
  • BMI ≥ 28 kg/m², or 24 kg/m² ≤ BMI \< 28 kg/m² and a clinical diagnosis meeting semaglutide treatment indications (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, cardiovascular disease, etc.).
  • Willingness to participate in this study and provide signed informed consent.

Exclusion Criteria29

  • Abnormal metabolic indicators (meeting any one of the following criteria is grounds for exclusion):
  • \. Normal weight (18.5 kg/m² ≤ BMI \< 24 kg/m²):
  • Waist circumference ≥ 90 cm for men or ≥ 85 cm for women.
  • Fasting glucose ≥ 6.1 mmol/L or 2-hour postprandial glucose ≥ 7.8 mmol/L, or a confirmed diagnosis of diabetes.
  • Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, or currently under antihypertensive treatment.
  • Fasting triglycerides (TG) ≥ 1.7 mmol/L; high-density lipoprotein cholesterol (HDL-C) \< 0.9 mmol/L in men or \< 1.0 mmol/L in women.
  • \. Overweight or obese (BMI ≥ 24 kg/m²):
  • Fasting plasma glucose \> 11.1 mmol/L or HbA1c \> 9%, or previously diagnosed diabetes, or currently using insulin or any antidiabetic medication.
  • Blood pressure ≥ 160/100 mmHg, or clinically diagnosed stage 2 or stage 3 (moderate or severe) hypertension, or currently under antihypertensive treatment.
  • Use of lipid-lowering drugs (e.g., fibrates, bile acid sequestrants, statins, PCSK9 inhibitors) within the past 3 months, or TG ≥ 5.7 mmol/L, or LDL ≥ 4.9 mmol/L.
  • Pregnancy or lactation.
  • Self-reported weight change of more than 5 kg within the 90 days prior to screening.
  • Use of antibiotics, antimicrobials, or anti-inflammatory/analgesic salicylates (e.g., aspirin) within the 3 months prior to screening for 3 days or more.
  • Use of estrogen therapy or other hormonal medications within the past 6 months.
  • Use of GLP-1 receptor agonists or probiotics within the past 3 months.
  • Heavy alcohol consumption (females \> 40 g/day, approximately 250 mL of huangjiu \[yellow rice wine\], or 1000 mL of beer, or 100 mL of liquor per day; males \> 80 g/day).
  • Severe liver or kidney dysfunction (ALT, AST, or serum creatinine exceeding 3 times the upper limit of normal, UACR ≥ 30 mg/g, or eGFR \< 60 mL/min).
  • Gastrointestinal diseases affecting digestion and absorption (e.g., severe diarrhea, severe constipation, severe inflammatory bowel disease, peptic ulcer, gallstones, cholecystitis).
  • Underwent surgery within the past year (excluding appendectomy or hernia repair).
  • Severe cardiovascular or cerebrovascular diseases (e.g., heart failure, myocardial infarction, stroke, acute myocarditis, severe arrhythmia, or receiving interventional therapy).
  • Presence of metallic implants such as a cardiac stent or pacemaker.
  • Cancer or having received radiation or chemotherapy within the past 5 years.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, or a personal history of hyperthyroidism or hypothyroidism.
  • Chronic or acute pancreatitis.
  • Positive hepatitis B surface antigen (HBsAg), active tuberculosis, HIV, or other infectious diseases.
  • Currently participating in another clinical study or having done so within the past 3 months.
  • Claustrophobia.
  • Any psychiatric disorder such as attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, or epilepsy (including current use of antiepileptic medications), or use of antidepressant medications.
  • Inability to read, write, operate a smartphone, or perform daily activities independently.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALGeneral lifestyle and nutritional education

Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.

BEHAVIORALEnergy-restricted nutritional and lifestyle intervention

Participants will receive dietary advice, behavioral guidance and nutritional and lifestyle education by dietitian and physicians. App-connected wearable devices will be utilized to monitor their dietary intakes and App-connected scale will be used to monitor their weight changes during interventions.

DIETARY_SUPPLEMENTPlacebo

Participants will receive one bag (2 g; 1 × 10¹² CFU) daily of LC-19.

DIETARY_SUPPLEMENTProbiotic

participants will receive daily one bag of LC-19 (10\^12 cfu/bag).

DRUGsemaglutide

Participants will receive prescibed semaglutide therapy


Locations(1)

Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06989177


Related Trials